Bingham Private Wealth LLC Reduces Stake in Pfizer Inc. $PFE

Bingham Private Wealth LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 3.7% during the second quarter, Holdings Channel.com reports. The institutional investor owned 14,152 shares of the biopharmaceutical company’s stock after selling 547 shares during the period. Bingham Private Wealth LLC’s holdings in Pfizer were worth $343,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Bessemer Group Inc. boosted its position in Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after buying an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK boosted its position in Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after buying an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in Pfizer in the first quarter valued at approximately $8,283,000. Westbourne Investments Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. boosted its position in Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after buying an additional 18,200 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 3.4%

Shares of PFE stock opened at $26.45 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market cap of $150.38 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 0.88 and a beta of 0.55. The stock has a 50 day simple moving average of $24.72 and a 200-day simple moving average of $24.12. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on PFE. Bank of America upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Finally, Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.